Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases
MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-ho...
Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study
MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study inthe United States. BioMUSE is a natur...
New data independently confirms and extends laboratory findings and expands safety profile of ATH434
MELBOURNE, Australia and SAN FRANCISCO, Aug. 3, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for present...
Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report
Highlights: * FDA provides guidance for ATH434 development pathway * Company compliant with minimum NASDAQ price * End of period cash balance of $9.2M bolstered by $1.5M following issue of shares on 2 July MELBOURNE, Australia and SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- Alterity Therap...
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
MELBOURNE, Australia and SAN FRANCISCO, June 29, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 ...
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
MELBOURNE, Austrilia and SAN FRANCISCO, May 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting....
Alterity Therapeutics Limited Releases Its Appendix 4C - Q3 FY20 Quarterly Cash Flow Report
Highlights: * European Commission designated Orphan Drug status for ATH434's treatment of Multiple System Atrophy in the European Union * Phase 2 preparatory work continues * Cash balance of $10.4M MELBOURNE, Australia and SAN FRANCISCO, April 30, 2020 /PRNewswire/ -- Alterity Therapeutics ...
Alterity Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement
MELBOURNE, Australia and SAN FRANCISCO, Feb. 7, 2020 /PRNewswire/ -- Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) has received notification from the Listing Qualifications Department of NASDAQ advising the Company that it is currently non-compliant with NASDAQ's requirement that listed se...
